NCT07915791ClinicalTrials.gov
A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
ALARMONY: A Phase 2 Randomized, Double Blind, Placebo Controlled Multi-center Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe COPD
In breve
This study is for adult participants with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who continue to experience exacerbations despite standard of care triple therapy treatment. It will assess the effectiveness and safety of two investigational drugs, GSK3862995B and…
Fase 2279 partecipanti ricercati10 centri2 paesi
Categorie
Registrato in 1 registro
- ClinicalTrials.govNCT07915791Apri questa scheda su ClinicalTrials.govSincronizzato l’altro ieri
Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.
Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.
Ti interessa questo studio?
Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 6 days after the recorded start)First posted 2026-11-04; recorded start 2026-10-29
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 336 other studies in this databaseCounted from the lead sponsor named in the record (GlaxoSmithKline)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding16/20
Triple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 10 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 279 participants (target), run at 10 sites, across 2 countries.
How this score is built
- Enrolment24/40
279 participants (target)
- Site count12/25
10 sites
- Country count7/15
2 countries
- Planned duration8/10
Planned over about 40 months
- Sponsor scale9/10
GlaxoSmithKline has led 337 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Sintesi
This study is for adult participants with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who continue to experience exacerbations despite standard of care triple therapy treatment. It will assess the effectiveness and safety of two investigational drugs, GSK3862995B and GSK5784283, given together compared to a placebo in addition to standard of care.
Patologie
- Pulmonary Disease, Chronic Obstructive
Idoneità
| Sesso | Tutti |
|---|---|
| Età | 40 Years – 80 Years |
| Volontari sani | No |
Idoneità come riportata nel registro
Idoneità in frasi semplici
I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.
Disegno dello studio
| Tipo di studio | Interventistico |
|---|---|
| Fase | Fase 2 |
| Assegnazione | Randomizzata |
| Modello di intervento | PARALLEL |
| Finalità principale | TREATMENT |
| Mascheramento | TRIPLE (3) |
| Arruolamento | 279 partecipanti ricercati |
Sponsor e collaboratori
- GlaxoSmithKline Sponsor
Bracci e interventi
- GSK3862995B co-administered with GSK5784283EXPERIMENTAL
Participants will receive co-administration of GSK3862995B and GSK5784283 in addition to their standard of care (SoC) triple therapy for COPD.
- PlaceboPLACEBO_COMPARATOR
Participants will receive a matching placebo in addition to their SoC triple therapy for COPD.
Interventi
- Farmaco GSK3862995B
Participants will receive GSK3862995B.
- Farmaco GSK5784283
Participants will receive GSK5784283.
- Farmaco Placebo
Participants will receive matching Placebo.
Esiti misurati
Esito primario
Annualized Rate of Moderate/severe Exacerbations in Former Smokers
A moderate exacerbation is defined as a clinically significant exacerbation that requires treatment with oral/systemic corticosteroids and/or antibiotics. A severe exacerbation is defined as a clinically significant exacerbation that that requires in-patient hospitalization or results in death. The annualized rate will be derived using exacerbations data collected during the study for former smokers.
Orizzonte temporale Up to 72 weeks
Esito secondario
Number of Participants with Serious Adverse Events and Adverse Events in All Comers (Former and Current smokers) with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Orizzonte temporale Up to 120 weeks
Esito secondario
Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory Parameters, Vital Signs, and 12-Lead Electrocardiogram (ECG) in All Comers (Former and Current smokers) with Moderate to Severe COPD
Orizzonte temporale Up to 120 weeks
Esito secondario
Time to First Exacerbation in Former Smokers with Moderate to Severe COPD
Orizzonte temporale Up to 72 weeks
Esito secondario
Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) at Week 24 in Former Smokers with Moderate to Severe COPD
Orizzonte temporale Baseline and Week 24
Esito secondario
Change from Baseline in SGRQ-C total score at Week 24 in Former Smokers with Moderate and Severe COPD
The SGRQ C is a validated, disease specific patient reported outcome instrument used to assess health related quality of life in patients with chronic obstructive pulmonary disease (COPD), capturing the impact of respiratory symptoms, activity limitations, and psychosocial effects of the disease. It calculates domain scores (Symptoms, Activity, and Impacts) and an overall Total Score based on weighted responses to approximately 40 questionnaire items, which yield to a score ranges from 0 (no impairment; best health status) to 100 (maximum impairment; worst health status).
Orizzonte temporale Baseline and Week 24
Esito secondario
Change from baseline in the COPD Assessment Test (CAT) Score at Week 24 in Former Smokers with Moderate to Severe Smokers
The CAT is a short, patient-completed questionnaire developed to measure the health status of individuals with Chronic Obstructive Pulmonary Disease (COPD). The CAT consists of 8 items, and for each item, the participant provides a rating on a 6-point scale from 0 (representing no impairment) to 5 (representing maximum impairment). A total score is derived by summing the scores of the 8 items, resulting in a scoring range of 0 to 40. Higher scores indicate a greater impact of the disease on the participants health.
Orizzonte temporale Baseline and Week 24
Esito secondario
Change from baseline in the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) score at Week 24 in Former Smokers with Moderate to Severe COPD
The E-RS: COPD is a patient-reported outcome diary developed to measure the severity of respiratory symptoms in patients with stable COPD. It consists of 11 respiratory symptom items from the 14-item EXAcerbations of Chronic pulmonary disease Tool (EXACT). Participants complete the diary each evening, rating their symptoms for that day. The E-RS: COPD total score is calculated by summing the responses to the 11 items, with a scoring range of 0 to 40. Higher scores indicate more severe respiratory symptoms. The instrument also includes three subscales: Breathlessness (5 items; score range 0-17), Cough and Sputum (3 items; score range 0-11), and Chest Symptoms (3 items; score range 0-12). The E-RS: COPD is designed to capture symptoms such as breathlessness, cough, sputum production, chest congestion, and chest tightness.
Orizzonte temporale Baseline and Week 24
Esito secondario
Annualized rate of Moderate/Severe Exacerbations in all Comers (Former and Current smokers)
A moderate exacerbation is defined as a clinically significant exacerbation that requires treatment with oral/systemic corticosteroids and/or antibiotics. A severe exacerbation is defined as a clinically significant exacerbation that that requires in-patient hospitalization or results in death. The annualized rate will be derived using exacerbations data collected during the study for former smokers.
Orizzonte temporale Up to 72 weeks
Esito secondario
Time to First Exacerbation in all Comers (Former and current Smokers) with Moderate to Severe COPD
Orizzonte temporale Up to 72 weeks
Esito secondario
Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) at Week 24 in all comers (Former and Current Smokers) with Moderate to Severe COPD
Orizzonte temporale Baseline and Week 24
Esito secondario
Change from Baseline in SGRQ-C total score at Week 24 in all Comers (Former and Current Smokers) with Moderate and Severe COPD
The SGRQ C is a validated, disease specific patient reported outcome instrument used to assess health related quality of life in patients with chronic obstructive pulmonary disease (COPD), capturing the impact of respiratory symptoms, activity limitations, and psychosocial effects of the disease. It calculates domain scores (Symptoms, Activity, and Impacts) and an overall Total Score based on weighted responses to approximately 40 questionnaire items, which yield to a score ranges from 0 (no impairment; best health status) to 100 (maximum impairment; worst health status).
Orizzonte temporale Baseline and Week 24
Esito secondario
Change from baseline in the CAT Score at Week 24 all Comers (Former and Current Smokers) with Moderate to Severe Smokers
The CAT is a short, patient-completed questionnaire developed to measure the health status of individuals with Chronic Obstructive Pulmonary Disease (COPD). The CAT consists of 8 items, and for each item, the participant provides a rating on a 6-point scale from 0 (representing no impairment) to 5 (representing maximum impairment). A total score is derived by summing the scores of the 8 items, resulting in a scoring range of 0 to 40. Higher scores indicate a greater impact of the disease on the participants health.
Orizzonte temporale Baseline and Week 24
Esito secondario
Change from baseline in the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) score at Week 24 in all comers (Former and current Smokers) with Moderate to Severe COPD
The E-RS: COPD is a patient-reported outcome diary developed to measure the severity of respiratory symptoms in patients with stable COPD. It consists of 11 respiratory symptom items from the 14-item EXAcerbations of Chronic pulmonary disease Tool (EXACT). Participants complete the diary each evening, rating their symptoms for that day. The E-RS: COPD total score is calculated by summing the responses to the 11 items, with a scoring range of 0 to 40. Higher scores indicate more severe respiratory symptoms. The instrument also includes three subscales: Breathlessness (5 items; score range 0-17), Cough and Sputum (3 items; score range 0-11), and Chest Symptoms (3 items; score range 0-12). The E-RS: COPD is designed to capture symptoms such as breathlessness, cough, sputum production, chest congestion, and chest tightness.
Orizzonte temporale Baseline and Week 24
Esito secondario
Serum concentrations of GSK3862995B and GSK5784283 in all comers (former and current smokers) with moderate to severe COPD
Orizzonte temporale Week 2; pre-dose on Weeks 12, 24, 36, 48, 60; and Week 72
Date
| Data di inizio | 29 ottobre 2026 (effettiva) |
|---|---|
| Conclusione primaria | 7 marzo 2029 (stimata) |
| Conclusione | 6 febbraio 2030 (stimata) |
| Prima pubblicazione | 4 novembre 2026 (effettiva) |
| Ultimo aggiornamento | 17 novembre 2026 |
| Risultati pubblicati | Non indicato nella scheda del registro |
| Stato verificato l'ultima volta | novembre 2026 |
«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.
Centri
10 centri stanno reclutando
United Kingdom
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| GSK Investigational Site | Bradford | In reclutamento | |
| GSK Investigational Site | London | In reclutamento |
United States
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| GSK Investigational Site | Columbia | Maryland | In reclutamento |
| GSK Investigational Site | Derby | Kansas | In reclutamento |
| GSK Investigational Site | Miami | Florida | In reclutamento |
| GSK Investigational Site | Newport Beach | California | In reclutamento |
| GSK Investigational Site | Oklahoma City | Oklahoma | In reclutamento |
| GSK Investigational Site | Philadelphia | Pennsylvania | In reclutamento |
| GSK Investigational Site | Rock Hill | South Carolina | In reclutamento |
| GSK Investigational Site | Tomball | Texas | In reclutamento |
Documenti dello studio
In questa scheda del registro non sono collegati documenti.
Modifiche nel tempo
- 17 novembre 2026
Stato modificato
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 17 novembre 2026
Reclutamento aperto
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 17 novembre 2026
Data di conclusione anticipata
Primary completion advanced 9 days
2029-03-162029-03-07
- 17 novembre 2026
Centro aggiunto
10 sites added (10 total)
010